Loading clinical trials...
Loading clinical trials...
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema
Conditions
Interventions
BCX4161
Placebo
Locations
40
United States
Birmingham, Alabama, United States
Scottsdale, Arizona, United States
Granada Hills, California, United States
San Diego, California, United States
San Diego, California, United States
Walnut Creek, California, United States
Start Date
December 17, 2014
Primary Completion Date
January 1, 2016
Completion Date
January 1, 2016
Last Updated
November 17, 2025
NCT05762640
NCT06960213
NCT06716814
NCT06510699
NCT07001280
NCT07237048
Lead Sponsor
BioCryst Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions